THE SAGE GROUP Announces that Mary L. Yost, President, Will Lecture at the NEW CARDIOVASCULAR HORIZONS (NCVH) Second Annual “Understanding the Business of Peripheral Interventions” Session
BEAUFORT SC, May 13, 2015 (BUSINESS WIRE)—Ms. Yost’s lecture titled, “The Economic Cost of PAD, CLI and Venous Disease: How Big Is the Market?” will be delivered on May 31, 2016 at the Business of Peripheral Interventions meeting. Part of the 17th annual NCVH meeting, this educational pre-event will be held from 8:30 am-5:00 pm at The Roosevelt Waldorf-Astoria in New Orleans, Louisiana. Course Directors are Craig M. Walker, MD and Mary L. Yost, MBA.
“This all-day session is a unique and much needed educational offering,” Ms. Yost stated. “I do not believe that any other interventional or cardiovascular conferences offer anything comparable. If the topic is even covered, typically all that is offered on economics or costs of peripheral artery disease (PAD) and critical limb ischemia (CLI) is one lecture for an entire meeting.”
“The program of ‘The Business of Peripheral Interventions’ was structured to provide a comprehensive review of the current economic, financial and business issues surrounding peripheral and venous disease,” continued Yost. “In contrast to coronary disease, little research has been published on costs and the economic impact of PAD and CLI or on the costs and consequences of the different treatment options. There is a significant unmet need for additional information and more research on all business and economic aspects of PAD,” she explained.
According to THE SAGE GROUP, PAD is one of the most widespread chronic diseases. Currently afflicting almost 20 million U.S. citizens, PAD prevalence is exceeded only by diabetes and venous disease. Costing an estimated $200 to almost $400 billion, PAD direct disease costs exceed those of diabetes and coronary disease, as well as all cancers combined.
“Because PAD is so costly, physicians, hospital administrators, insurance companies and policy makers need to understand its significant macroeconomic impact as well as the relative costs and consequences of different treatment options–including amputation,” Yost stated.
Additional information and a detailed agenda for “The Business of PAD” can be found at: http://www.ncvh.org/meetings/business-of-peripheral-interventions/.
For more information on NCVH, including the conference program, or to register, visit
NCVH is an educational nonprofit foundation focused on multidisciplinary accredited conferences to advance the field of cardiovascular care using endovascular technologies, pharmacotherapy treatments, peripheral interventions and amputation prevention techniques. With a goal to empower healthcare providers with knowledge of head-to-toe vascular treatments, NCVH strives to promote interdisciplinary teamwork and collaboration to address the continuum of patient care. Additional information: http://www.ncvh.org/index.php.
About THE SAGE GROUP
THE SAGE GROUP, a research and consulting company, specializes in atherosclerotic and venous disease in the lower limbs, specifically PAD, CLI, intermittent claudication (IC) and ischemic diabetic foot ulcers (DFU). The most recent research focuses on quantifying the economic and social costs of PAD, CLI and amputation. Additional information: www.thesagegroup.us.
SOURCE: THE SAGE GROUP
THE SAGE GROUP, Beaufort SC
Mary Yost 404-520-6652